Treatment of hypertension in patients with diabetes mellitus

[1]  E. Ritz,et al.  Hypertonie beim Diabetes mellitus , 2006 .

[2]  Mark E Molitch,et al.  The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program. , 2006, Diabetes care.

[3]  David V. Power,et al.  Standards of Medical Care in Diabetes: Response to position statement of the American Diabetes Association , 2006 .

[4]  L. Smeeth,et al.  Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis , 2005, The Lancet.

[5]  L. Lindholm,et al.  Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis , 2005, The Lancet.

[6]  R. Schmieder,et al.  Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. , 2005, Journal of the American Society of Nephrology : JASN.

[7]  H. Parving,et al.  Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. , 2005, Kidney international.

[8]  Arya M. Sharma,et al.  Weight Loss and the Renin-Angiotensin-Aldosterone System , 2005, Hypertension.

[9]  T. Mengden,et al.  [24-hour blood pressure and ECG monitoring in patients with arterial hypertonia -- importance of silent myocardial ischemia]. , 2004, Deutsche medizinische Wochenschrift.

[10]  M. Pfeffer,et al.  Angiotensin-converting-enzyme inhibition in stable coronary artery disease. , 2004, The New England journal of medicine.

[11]  H. Yoshimatsu,et al.  Microalbuminuria, cardiovascular autonomic dysfunction, and insulin resistance in patients with type 2 diabetes mellitus. , 2004, Metabolism: clinical and experimental.

[12]  J. Laragh,et al.  Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial , 2004, The Lancet.

[13]  H. Häring,et al.  Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. , 2004, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[14]  Ross T Tsuyuki,et al.  Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes. , 2004, Diabetes care.

[15]  J F Potter,et al.  Extract from : , 2009 .

[16]  K. Fox,et al.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.

[17]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[18]  L. Lindholm,et al.  Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study) , 2003, Journal of hypertension.

[19]  Arya M. Sharma,et al.  The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? , 2003, The international journal of biochemistry & cell biology.

[20]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[21]  T. Mengden,et al.  ST-segment depression in hypertensive patients is linked to elevations in blood pressure, pulse pressure and double product by 24-h Cardiotens monitoring , 2003, Journal of hypertension.

[22]  A. Hofman,et al.  The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial , 2003, Journal of hypertension.

[23]  C. Reid,et al.  A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. , 2003, The New England journal of medicine.

[24]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[25]  G. Wolf,et al.  The Renin-Angiotensin System and Progression of Renal Disease: From Hemodynamics to Cell Biology , 2002, Nephron Physiology.

[26]  J. Redón,et al.  Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. , 2002, The New England journal of medicine.

[27]  P. Andrews.  NICE guidelines: renal disease — prevention and early management , 2002 .

[28]  G. Noll,et al.  Effects of Chronic Calcium Channel Blockade on Sympathetic Nerve Activity in Hypertension , 2002, Hypertension.

[29]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[30]  U. de Faire,et al.  Comparative Effects of Ramipril on Ambulatory and Office Blood Pressures: A HOPE Substudy , 2001, Hypertension.

[31]  M. Woodward,et al.  Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .

[32]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[33]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[34]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[35]  R. Düsing,et al.  [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)]. , 2001, Deutsche medizinische Wochenschrift.

[36]  W. Grzeszczak,et al.  Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? , 2001, Journal of the American Society of Nephrology : JASN.

[37]  P. Valensi,et al.  Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. , 2001, Diabetes care.

[38]  D. J. Veldhuisen,et al.  Autonomic dysfunction in patients with mild heart failure and coronary artery disease and the effects of add‐on β‐blockade , 2001 .

[39]  L. Bouter,et al.  Cardiovascular autonomic function is associated with (micro-)albuminuria in elderly Caucasian sujects with impaired glucose tolerance or type 2 diabetes: the Hoorn Study. , 2000, Diabetes care.

[40]  Jagmeet P. Singh,et al.  Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). , 2000, The American journal of cardiology.

[41]  P. Grossman,et al.  Is there a glycemic threshold for impaired autonomic control? , 2000, Diabetes care.

[42]  R. Heethaar,et al.  Glucose tolerance and other determinants of cardiovascular autonomic function: the Hoorn Study , 2000, Diabetologia.

[43]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[44]  S. Yusuf,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[45]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[46]  D. Abernethy,et al.  Calcium-antagonist drugs. , 1999, The New England journal of medicine.

[47]  A. Smit,et al.  Baroreflex sensitivity is depressed in microalbuminuric Type I diabetic patients at rest and during sympathetic manoeuvres , 1999, Diabetologia.

[48]  J P Greenwood,et al.  Single-unit sympathetic discharge : quantitative assessment in human hypertensive disease. , 1999, Circulation.

[49]  W. Grimm,et al.  [Prospective evaluation of effect of carvedilol therapy on heart rate variability in patients with dilated cardiomyopathy]. , 1999, Zeitschrift fur Kardiologie.

[50]  Gianfranco Parati,et al.  Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. , 1999 .

[51]  P. Blankestijn,et al.  Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. , 1999, The New England journal of medicine.

[52]  G. Remuzzi.  Sympathetic overactivity in hypertensive patients with chronic renal disease. , 1999, The New England journal of medicine.

[53]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[54]  T. Lüscher,et al.  I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives. , 1998, Hypertension.

[55]  T. Saruta,et al.  The obese gene product, leptin: possible role in obesity‐related hypertension in adolescents , 1998, Journal of hypertension.

[56]  C. Ting,et al.  Differential Glucose Tolerance in Dipper and Nondipper Essential Hypertension: The implications of circadian blood pressure regulation on glucose tolerance in hypertension , 1998, Diabetes Care.

[57]  P. Rossing,et al.  Diabetes and Risk of Adverse Events With Calcium Antagonists , 1998, Diabetes Care.

[58]  M. Schachter,et al.  Safety and Tolerability of Moxonidine in the Treatment of Hypertension , 1998, Drug safety.

[59]  M. Vaage-Nilsen,et al.  Effect of Verapamil on Heart Rate Variability After an Acute Myocardial Infarction , 1998, Cardiovascular Drugs and Therapy.

[60]  K. Airaksinen,et al.  Vagal cardiac activity in essential hypertension: the effects of metoprolol and ramipril. , 1998, American journal of hypertension.

[61]  T. Lüscher,et al.  Role of sympathetic nervous system in hypertension and effects of cardiovascular drugs. , 1998, European heart journal.

[62]  M. Pahor,et al.  Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDM , 1998, Diabetes Care.

[63]  M. Schachter.  CENTRALLY ACTING ANTIHYPERTENSIVES: NOT OBSOLETE AFTER ALL , 1998, International journal of clinical practice.

[64]  B. Psaty,et al.  Treatment of hypertensive patients with diabetes , 1998, The Lancet.

[65]  R. Schrier,et al.  The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. , 1998, The New England journal of medicine.

[66]  I. Hisatome,et al.  Evaluation of changes in sympathetic nerve activity and heart rate in essential hypertensive patients induced by amlodipine and nifedipine , 1998, Journal of hypertension.

[67]  S. Jacob,et al.  Antihypertensive agent moxonidine enhances muscle glucose transport in insulin-resistant rats. , 1997, Hypertension.

[68]  F. Messerli,et al.  Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure. , 1997, The American journal of cardiology.

[69]  P. Laippala,et al.  Renal and cardiovascular predictors of 9-year total and sudden cardiac mortality in non-insulin-dependent diabetic subjects. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[70]  C. Thompson,et al.  Microalbuminuria: A Marker to Increased Renal and Cardiovascular Risk in Diabetes Mellitus , 1997, Scottish medical journal.

[71]  T. Lüscher,et al.  Differential activation of cardiac and peripheral sympathetic nervous system by nifedipine: role of pharmacokinetics. , 1997, Journal of the American College of Cardiology.

[72]  T. Lüscher,et al.  Differential effects of captopril and nitrates on muscle sympathetic nerve activity in volunteers. , 1997, Circulation.

[73]  P. Poulsen,et al.  24-h blood pressure and autonomic function is related to albumin excretion within the normoalbuminuric range in IDDM patients , 1997, Diabetologia.

[74]  D. Bonaduce,et al.  Comparison of verapamil versus felodipine on heart rate variability after acute myocardial infarction. , 1997, The American journal of cardiology.

[75]  P. Toutouzas,et al.  Effects of antihypertensive therapy on left atrial function. , 1996, Journal of human hypertension.

[76]  G. Schernthaner,et al.  Nondipping of nocturnal blood pressure is related to urinary albumin excretion rate in patients with type 2 diabetes mellitus. , 1996, American journal of hypertension.

[77]  H. Parving,et al.  Circadian rhythm of arterial blood pressure and albuminuria in diabetic nephropathy. , 1996, Kidney international.

[78]  L. Niskanen,et al.  Occurrence, Predictors, and Clinical Significance of Autonomic Neuropathy in NIDDM: Ten-Year Follow-Up From the Diagnosis , 1996, Diabetes.

[79]  G. Breithardt,et al.  Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. , 1996 .

[80]  B. Szabo,et al.  Mechanism of Sympathoinhibition by Imidazolines , 1995, Annals of the New York Academy of Sciences.

[81]  D. O'Connor,et al.  Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension. , 1995, Hypertension.

[82]  P. Poulsen,et al.  Ambulatory Blood Pressure in the Transition from Normo- to Microalbuminuria: A Longitudinal Study in IDDM Patients , 1994, Diabetes.

[83]  G. Viberti.  Prognostic significance of microalbuminuria. , 1994, American journal of hypertension.

[84]  K. Hermansen,et al.  Early recognition of autonomic dysfunction in microalbuminuria: significance for cardiovascular mortality in diabetes mellitus? , 1994, Diabetologia.

[85]  B. Prichard,et al.  Clinical experience with moxonidine , 1994, Cardiovascular Drugs and Therapy.

[86]  P. Ernsberger,et al.  A novel mechanism of action for hypertension control: Moxonidine as a selective I1-imidazoline agonist , 1994, Cardiovascular Drugs and Therapy.

[87]  L. Groop,et al.  Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria , 1994 .

[88]  L. Groop,et al.  Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. , 1994, JAMA.

[89]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[90]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[91]  T. Mano,et al.  Elevated sympathetic nerve activity in patients with accelerated essential hypertension. , 1993, The Journal of clinical investigation.

[92]  G. Sundkvist,et al.  Autonomic Neuropathy Predicts Deterioration in Glomerular Filtration Rate in Patients With IDDM , 1993, Diabetes Care.

[93]  M. Lishner,et al.  Long-Term Stabilizing Effect of Angiotensin-Converting Enzyme Inhibition on Plasma Creatinine and on Proteinuria in Normotensive Type II Diabetic Patients , 1993, Annals of Internal Medicine.

[94]  D. Faulds,et al.  Moxonidine. A review of its pharmacology, and therapeutic use in essential hypertension. , 1992, Drugs.

[95]  J. Christiansen,et al.  Circadian variation of blood pressure in patients with diabetic nephropathy , 1992, Diabetologia.

[96]  P. Fratino,et al.  Impaired Circadian Modulation of Sympathovagal Activity in Diabetes: A Possible Explanation for Altered Temporal Onset of Cardiovascular Disease , 1992, Circulation.

[97]  Claudio Cobelli,et al.  Power Spectral Analysis of Heart-Rate Variations Improves Assessment of Diabetic Cardiac Autonomic Neuropathy , 1992, Diabetes.

[98]  A. Vaag,et al.  Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European Type 2 (non-insulin-dependent) diabetic patients , 1991, Diabetologia.

[99]  A. Malliani,et al.  Cardiovascular Neural Regulation Explored in the Frequency Domain , 1991, Circulation.

[100]  H. Parving,et al.  Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. , 1991, BMJ.

[101]  W Kirch,et al.  Pharmacodynamic Action and Pharmacokinetics of Moxonidine After Single Oral Administration in Hypertensive Patients , 1990, Journal of clinical pharmacology.

[102]  I. Meredith,et al.  Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. , 1990, Physiological reviews.

[103]  A. Malliani,et al.  Continuous 24-hour assessment of the neural regulation of systemic arterial pressure and RR variabilities in ambulant subjects. , 1990, Circulation.

[104]  B. Brenner,et al.  Short and long term effects of antihypertensive therapy in the diabetic rat. , 1989, Kidney international.

[105]  E A Anderson,et al.  Elevated Sympathetic Nerve Activity in Borderline Hypertensive Humans Evidence From Direct Intraneural Recordings , 1989, Hypertension.

[106]  L. Navar,et al.  Disparate effects of Ca channel blockade on afferent and efferent arteriolar responses to ANG II. , 1989, The American journal of physiology.

[107]  P. Schwartz,et al.  Autonomic mechanisms and sudden death. New insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction. , 1988, Circulation.

[108]  G. Keating,et al.  Moxonidine: a review of its use in essential hypertension. , 2006 .

[109]  R. Düsing,et al.  Wechsel von ACE-Hemmer, Ca-Antagonist oder β-Blocker zu Candesartancilexetil: Bessere Wirksamkeit und Verträglichkeit - SWITCH-Studie (deutscher Studienteil) - , 2001 .

[110]  S. Yusuf,et al.  Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53. , 2000 .

[111]  R A Shaffer,et al.  Obesity-induced hypertension : New concepts from the emerging biology of obesity , 1999 .

[112]  G Mancia,et al.  Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure. , 1998, Hypertension.

[113]  T. Lüscher,et al.  Calcium antagonists and sympathetic nerve activation: are there differences between classes? , 1998, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[114]  H. Küppers,et al.  Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. , 1997, Journal of hypertension.

[115]  M. Weck,et al.  Impaired activation of the baroreflex loop as early sign of sympathetic damage in diabetics with normal heart rate variability at rest. , 1997, Acta medica Austriaca.

[116]  K. Irsigler,et al.  [Retrospective analysis of the incidence of severe hypoglycemia in 458 type 1 diabetic patients]. , 1997, Acta medica Austriaca.

[117]  H. Lithell.  Considerations in the treatment of insulin resistance and related disorders with a new sympatholytic agent , 1997, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[118]  P. Ernsberger,et al.  The I1‐imidazoline receptor: from binding site to therapeutic target in cardiovascular disease , 1997, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[119]  B. Spiess.  Ischemia--a coagulation problem? , 1996, Journal of cardiovascular pharmacology.

[120]  E. Verrier.  The microvascular cell and ischemia-reperfusion injury. , 1996, Journal of cardiovascular pharmacology.

[121]  J. Webster,et al.  Aspects of Tolerability of Centrally Acting Antihypertensive Drugs , 1996, Journal of cardiovascular pharmacology.

[122]  B. Prichard,et al.  Effective Antihypertensive Therapy: Blood Pressure Control with Moxonidine , 1996, Journal of cardiovascular pharmacology.

[123]  P. Ernsberger,et al.  Pharmacology of moxonidine, an I1-imidazoline receptor agonist. , 1996, Journal of cardiovascular pharmacology.

[124]  R. Baevsky,et al.  Hemodynamic regulation during postural tilt assessed by heart rate- and blood-pressure variability combined with impedance cardiography. , 1995, Wiener medizinische Wochenschrift.

[125]  J. Ollivier,et al.  I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience. , 1994, Journal of cardiovascular pharmacology.

[126]  P. Schwartz,et al.  Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. , 1992, Circulation.

[127]  A. Sasaki,et al.  Persistent albuminuria as an index of diabetic nephropathy in type 2 diabetic patients in Osaka, Japan-incidence, risk factors, prognosis and causes of death. , 1989, Diabetes research and clinical practice.

[128]  D. Adam,et al.  Assessment of autonomic function in humans by heart rate spectral analysis. , 1985, The American journal of physiology.